Choose your country to see the products for your location

SALSA MLPA Probemix P033 CMT1

Charcot-Marie-Tooth neuropathy (CMT); Neuropathy with liability to pressure palsies, hereditary (HNPP)

Region: CMT/HNPP region 17p12; KIF1b 1p36

Intended purpose
The SALSA MLPA Probemix P033 CMT1 is an in vitro diagnostic (IVD)1 or research use only (RUO) semi-quantitative assay2 for the detection of deletions or duplications in the human PMP22 and KIF1b genes in genomic DNA isolated from human peripheral whole blood specimens or buccal swabs. P033 CMT1 is intended to confirm a potential cause for and clinical diagnosis of Charcot-Marie-Tooth disease (CMT) or hereditary neuropathy with liability to pressure palsies (HNPP) and for molecular genetic testing of at-risk family members.

Copy number variations (CNVs) detected with P033 CMT1 should be confirmed with a different technique. In particular, CNVs detected by only a single probe always require confirmation by another method. Not all exons of KIF1b are covered. Some defects in PMP22 and most defects in KIF1b are point mutations, none of which will be detected by MLPA. It is therefore recommended to use this assay in combination with sequence analysis.

Assay results are intended to be used in conjunction with other clinical and diagnostic findings, consistent with professional standards of practice, including confirmation by alternative methods, clinical genetic evaluation, and counselling, as appropriate. The results of this test should be interpreted by a clinical molecular geneticist or equivalent.

This device is not intended to be used for standalone diagnostic purposes, pre-implantation or prenatal testing, population screening, or for the detection of, or screening for, acquired or somatic genetic aberrations.

1 Please note that this probemix is for In Vitro Diagnostic (IVD) use in the countries specified at the end of this product description. In all other countries, the product is for Research Use Only (RUO).
2 To be used in combination with a SALSA MLPA Reagent Kit and Coffalyser.Net analysis software.

Clinical background
Charcot-Marie-Tooth disease (CMT), with a worldwide incidence of 1 in 2500, is the most common hereditary sensorimotor neuropathy, comprising a group of clinically and genetically heterogeneous peripheral neuropathies. CMT is characterized by progressive distal muscle atrophy and weakness, sensory disturbance, the absence of deep tendon reflexes, and pes cavus deformity of the foot. More than 80 different genes are associated with CMT ( Subtypes related to the genes PMP22, GJB1, MPZ and MFN2 are the most common ones, being responsible for up to 95% of CMT cases with a final diagnosis (Padilha et al. 2020). The disease can be inherited in an autosomal dominant, autosomal recessive or X-linked manner. Table 1 provides an overview of the different genes involved in the CMT subtypes and the probemixes that cover these genes.

The most frequent form, CMT1A, accounts for as much as 50% of all CMT cases. CMT1A is a dominantly inherited, childhood-onset, slowly progressive motor and sensory neuropathy due to a duplication of PMP22 on chromosome 17. CMT type 2 is an axonal peripheral neuropathy which shows extensive clinical overlap with CMT1. However, in general, the phenotype of CMT2 patients is less severe. Until now, >15 subtypes of CMT2 have been described, each involving a different gene or chromosomal locus. Haploinsufficiency for the KIF1b gene is suggested to be responsible for CMT type 2A (Zhao et al. 2001; Drew et al. 2015).

Hereditary neuropathy with liability to pressure palsies (HNPP) is characterized by repeated focal pressure neuropathies such as carpal tunnel syndrome and peroneal palsy with foot drop. Recovery from acute neuropathy is often complete; when recovery is not complete, the resulting disability is usually mild. Some affected individuals also have signs of a mild to moderate peripheral neuropathy. The prevalence of HNPP is estimated at 7-16 in 100,000. The penetrance is 100% but expressivity is highly variable even within the same family. Approximately 6-23% of individuals diagnosed with HNPP have an asymptomatic affected parent. A contiguous gene deletion of chromosome 17p12 that includes PMP22 is present in approximately 80% of affected individuals; the remaining 20% have a pathogenic variant in PMP22 (

Table 1. Overview of the probemixes and genes related to CMT.
Probemix* Genes and coverage Condition Remarks
P033-B4 CMT1 (IVD) PMP22: all exons
KIF1b: 2 probes
PMP22 probes in P033-B4 have the same ligation site as PMP22 probes in P405-B1 except for one exon 1 probe and one exon 4 probe. There is one additional PMP22 exon 5 probe present in P033-B4.
P405-B1 CMT1 (IVD) PMP22: all exons
MPZ: all exons
GJB1: all exons
PMP22 probes in P405-B1 have the same ligation sites as PMP22 probes in P033-B4 except for one exon 1 probe and one exon 4 probe. There is one additional PMP22 exon 5 probe present in P033-B4.
MPZ probes in P405-B1 have the same ligation sites as MPZ probes in P143-C3.
P143-C3 MFN2-MPZ (RUO) MFN2: all exons
MPZ: all exons
MPZ probes in P143-C3 have the same ligation sites as MPZ probes in P405-B1.
*IVD: in vitro diagnostic. RUO: research use only.

Probemix content
The SALSA MLPA Probemix P033-B4 CMT1 contains 38 MLPA probes with amplification products between 130 and 436 nucleotides (nt). This includes 16 probes for the common 17p12 deletion/duplication region, two flanking probes for genes outside the common 17p12 deletion/duplication region, and two probes for the KIF1b gene. In addition, 18 reference probes are included that detect autosomal chromosomal locations. Complete probe sequences and the identity of the genes detected by the reference probes are available online (

This probemix contains nine quality control fragments generating amplification products between 64 and 105 nt: four DNA Quantity fragments (Q-fragments), two DNA Denaturation fragments (D-fragments), one Benchmark fragment, and one chromosome X and one chromosome Y-specific fragment. More information on how to interpret observations on these control fragments can be found in the MLPA General Protocol and online at

Order Items


Item no.
SALSA MLPA Probemix P033 CMT1 – 25 rxn
€ 281.00
SALSA MLPA Probemix P033 CMT1 – 50 rxn
€ 550.00
SALSA MLPA Probemix P033 CMT1 – 100 rxn
€ 1075.00

Required Reagents (Sold Separately)

Item no.
SALSA MLPA Reagent Kit – 100 rxn – FAM
€ 341.00
SALSA MLPA Reagent Kit – 100 rxn – Cy5
€ 341.00
SALSA MLPA Reagent Kit – 500 rxn – FAM
€ 1571.00
SALSA MLPA Reagent Kit – 500 rxn – Cy5
€ 1571.00
SALSA MLPA Reagent Kit – 2000 rxn – FAM
€ 6037.00

Related Products


Contains probes for the MFN2 and MPZ genes.

SALSA MLPA Probemix P307 SEPT9

Contains probes for the SEPT9 gene involved in hereditary neuralgic amyotrophy.

Improved Jun 17, 2024

SALSA MLPA Probemix P369 Smith-Magenis

Contains probes for the 17p11.2 Smith-Magenis region.

SALSA MLPA Probemix P405 CMT1

Contains probes for the 17p12 chromosomal region and the GJB1 and MPZ genes.

Sign in

Don't have an account? Create one

Forgot password?

Select Your Country

Choose your country to see the products for your location


One target, five reference probe replaced, ten target, two reference probes added.


CE-marked products are for In Vitro Diagnostic (IVD) use only in EU (candidate) member states and members of the European Free Trade Association (EFTA), and the UK.


IVD-registered in Colombia.


IVD-registered in Costa Rica.


IVD-registered in Israel.